Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 381 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Breast MRI Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

NCT01219075
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
soy isoflavones, placebo, questionnaire administration, magnetic resonance imaging, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, mammography
Dietary Supplement · Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 17, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 17, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Results available

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

NCT04750473
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 17, 2026, 4:09 PM EDT
Completed Not applicable Interventional Results available

The Prone to Supine Breast MRI Trial

NCT03573804
View directory record Official record
Conditions
Breast Cancer
Interventions
Prone to Supine MRI
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 17, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

NCT00602043
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography, computed tomography, laboratory biomarker analysis
Radiation · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 17, 2026, 4:09 PM EDT
Active, not recruiting Phase 1 Interventional

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

NCT02453620
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 4:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammation-Induced CNS Glutamate During Breast Cancer Treatment

NCT02421978
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 17, 2026, 4:09 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer

NCT03400215
View directory record Official record
Conditions
Breast Cancer
Interventions
Diagnostic Breast Cancer Scan, Research Scan for Gradient-echo Spectroscopic Imaging (GSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 99 Years · Female only
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 17, 2026, 4:09 PM EDT
Withdrawn Not applicable Interventional

Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer

NCT01791998
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer
Interventions
magnetic resonance thermal imaging, laser interstitial thermal therapy
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 17, 2026, 4:09 PM EDT
Recruiting No phase listed Observational

Magnetic Resonance Imaging in Radiotherapy for Breast Cancer

NCT05902507
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic Resonance Imaging Simulation
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 17, 2026, 4:09 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging in Patients With Breast Cancer

NCT00610181
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 17, 2026, 4:09 PM EDT
Not yet recruiting Not applicable Interventional

Low-dose Imaging TechniquE in Breast MRI

NCT07864519
View directory record Official record
Conditions
Breast MRI
Interventions
Standard of care contrast agent, provided in split dose, Breast MRI
Drug · Diagnostic Test
Lead sponsor
Manojkumar Saranathan
Other
Eligibility
30 Years to 89 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 4:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Myocardial Perfusion and Fibrosis in Cancer Survivors

NCT03191461
View directory record Official record
Conditions
Myocardial Fibrosis, Myocardial Injury, Chemotherapeutic Toxicity
Interventions
Adenosine stress test MRI
Diagnostic Test
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 17, 2026, 4:09 PM EDT
Withdrawn Not applicable Interventional

Partial Breast Irradiation in a Low-risk Population Screened With MRI

NCT01255553
View directory record Official record
Conditions
Breast Cancer
Interventions
Partial Breast Irradiation
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
40 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 17, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

NCT03179904
View directory record Official record
Conditions
Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
Interventions
Anastrozole, Denifanstat, Exemestane, Fulvestrant, Echocardiography, Letrozole, Paclitaxel, Trastuzumab, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy
Drug · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:09 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Molecular Imaging of Breast Cancer With Breast PET/CT

NCT00584753
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron emission tomography and computed tomography
Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 17, 2026, 4:09 PM EDT
Completed Phase 2 Interventional

MRI-Guided Ultrasound Energy in Treating Patients With Stage I, Stage II, or Stage IIIA Breast Cancer

NCT00008437
View directory record Official record
Conditions
Breast Cancer
Interventions
high-intensity focused ultrasound ablation
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Oct 17, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Intraoperative Radiotherapy for Early Stage Breast Cancer

NCT01189851
View directory record Official record
Conditions
Breast Cancer
Interventions
Intraoperative Radiotherapy
Device
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
48 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 17, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Denosumab and MRI Breast Imaging

NCT02613416
View directory record Official record
Conditions
Breast Cancer
Interventions
Denosumab
Drug
Lead sponsor
Alison Stopeck
Other
Eligibility
Up to 75 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 17, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants

NCT00474604
View directory record Official record
Conditions
Breast Cancer
Interventions
diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopic imaging
Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 17, 2026, 4:09 PM EDT
Recruiting Phase 2 Interventional

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT06179303
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing, Exemestane, Fludeoxyglucose F-18, Fluorine F 18 Fluoro Furanyl Norprogesterone, Fulvestrant, Gonadotropin-releasing Hormone Analog, Letrozole, Positron Emission Tomography, Tamoxifen, Therapeutic Estradiol
Drug · Procedure · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 4:09 PM EDT
Recruiting Phase 3 Interventional

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

NCT07357298
View directory record Official record
Conditions
Breast Cancer
Interventions
Surveillance Brain MRI, Standard of Care Brain Imaging
Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 4:09 PM EDT
Terminated Phase 2 Interventional Results available

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

NCT05554354
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fulvestrant, Magnetic Resonance Imaging, Multigated Acquisition Scan
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
192
States / cities
Birmingham, Alabama • Kingman, Arizona • Arroyo Grande, California + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 17, 2026, 4:09 PM EDT
Terminated Phase 1 Interventional Results available

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

NCT05035407
View directory record Official record
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 17, 2026, 4:09 PM EDT